

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

**Complete if Known**

Application Number	10/500,964
Filing Date	July 8, 2004
First Named Inventor	Sugasawa, Keizo
Art Unit	1625
Examiner Name	Chang, Cecelia C.
Attorney Docket Number	401.1013US

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1*
TCU	AD	Country Code* Number* Kind Code* (if known) WO 01/53267			Abstract	
	AE	WO 00/35446				
	AF	WO 04/029049			Abstract	
	AG	WO 2005/007651			Abstract	
	AH	WO 2005/014561			Abstract	
TCU	AO	WO 03/103657			Abstract	

Examiner Signature	/Celia Chang/	Date Considered	07/29/2008
-----------------------	---------------	--------------------	------------

\*EXAMINER: Include *if* reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.57 and 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**Sheet **3** of **3**

<b>Application Number</b>	10/500,964
<b>Filing Date</b>	July 8, 2004
<b>First Named Inventor</b>	Sugasawa, Keizo
<b>Art Unit</b>	1625
<b>Examiner Name</b>	Chang, Cecelia C.
<b>Attorney Docket Number</b>	401.1013US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/CC/	CA	KIMURA, TATSUYA, et al., "A non-peptide compound which can mimic the effect of thrombopoietin via e-mp1", FEBS Letters. 428,1998, 250-254	
	CB	International Search Report for WO 2005/007651, corresponding to U.S. Appl. serial no. 10/564,520.	
	CC	International Preliminary Report on Patentability from International Application no. PCT/IB2006/003142 (corresponding to US 11/593,758).	
	CD	KUTER, et al., "Recombinant Human Thrombopoietin: Basic Biology and Evaluation of Clinical Studies, Blood 2002, vol. 100, no. 10	
	CE	VADHAN-RAJ, et al., "Recom. Hum. Thrombopoietin Attenuates Carboplatin-Induced Svre. Thrombocytopenia", Annals of Internal Medicine 2002, vol. 132, no. 5, pp 364-368	
	CF	VADHAN-RAJ, et al., "Import. of Predosing of Recomb. Hum. Thrombopoietin to Rdce. Chemotherapy-Induced Ery.", Journal of Clinical Oncology 2003, Vol 21, No. 16, pp 3158-3167	
/CC/	CG	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects", 1005, CRC Press, pp 6-8	

<b>Examiner Signature</b>	/Celia Chang/	<b>Date Considered</b>	/Celia Chang/
---------------------------	---------------	------------------------	---------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.